New Links for Members
You asked, We brought 'em
Why CEU's
Support where you need it
A self-governing body, the OSCT admits and revokes membership in the Society and encourages all members to maintain professional standards by participating in a Continuing Education Units (CEU) system. With technology advancing so rapidly, the OSCT is working to upgrade and maintain national professional standards in the field of Cardiac testing. Today we have over 1100 Associate and Registered members in Ontario, Canada.
CEU Information
PLEASE NOTE:
The O.S.C.T. have released a survey to consult with their membership on their CEU process preferences.
The board will be meeting June 6th to discuss how to implement your wishes in the best way possible to comply with the high standards of regulation and for your ease of use and convenience.
*Please stay tuned for the new CEU process!
Free CEU Links
CEU Guidelines
New Standards Coming Soon
EP Lab Efficiencies
EP Lab Efficiencies Description:
To ensure optimal care and outcomes for patients with atrial fibrillation, hospitals and electrophysiologists will need to take a systems-based approach to EP lab efficiency, focused on standardizing processes while reducing waste and errors. Fortunately, the same processes used to achieve improvement in patient safety and outcomes, and even facilitate research, can simultaneously result in improved capacity.
On May 27-28, 2021, a group of Heart Rhythm Society members and staff visited Dr. Jose Osorio and his EP team at Grandview Medical Center in Birmingham, Alabama. The purpose of the visit was to learn about the improvement processes put in place to enhance both quality and efficiency. HRS members in attendance included electrophysiologists at different stages of their own quality improvement journeys. This video series captures the group's observations and the many lessons learned during the visit. The group describes how the transformational approach to quality improvement that Dr. Osorio and his team have implemented successfully at their program in Birmingham can be accomplished in EP labs everywhere.
Learners will be able to view the full series of 7 videos or select only the topics and sections of interest. Transcripts for each video are also provided.
The 7 videos cover the following areas of focus:
(1) why EP labs should focus on efficiency;
(2) an explanation of the Grandview model;
(3) how to implement principles of quality improvement in an EP lab;
(4) the importance of team member involvement;
(5) the relationship between electrophysiology and anesthesiology departments;
(6) engagement with the patient and caregiver; and
(7) reproducing the model in your own institution.
Learning Objectives Upon completion of this activity, participant should be able to:
1. Describe how to standardize processes to achieve better outcomes.
2. Create a cohesive team environment, improve staff morale, and reduce turnover by involving staff in setting expectations and by creating predictable work schedules.
3. Develop a standard protocol for the patient experience.
4. Construct processes, identify benchmarks, set expectations, and measure improvements.
5. Describe how to reduce turnover time.
6. Explain how to work with the anesthesiology department to schedule patients and implement protocols that improve patient care.
7. Determine a plan for implementing efficiency in the EP lab.
Target Audience
This activity is intended for all who study and treat heart rhythm disorders.
TAVR in Patients with Bicuspid Anatomy: Considerations in Patient Selection
Duration: 1 hour
CEU Value: 1
CSCT CEU STANDARDS SECTION: 2F
Link: TAVR in Patients with Bicuspid Anatomy | myCME
Expires: November 16, 2022
Description:
Program Description
Although patients with a bicuspid aortic valve (BAV) currently account for nearly half of aortic valve replacement (AVR) procedures, they were excluded from the pivotal clinical trials leading to US Food and Drug Administration approval of transcatheter AVR (TAVR). Nevertheless, there is a robust body of real-world data documenting good outcomes with TAVR in this population. In this Expert Perspectives webinar, three noted cardiologists review how the distinct morphologic features of bicuspid valves may impact TAVR outcomes and provide insights on the factors that determine which patients with bicuspid anatomy are candidates for TAVR and which may be better served by a traditional surgical approach.
TAVR in Bicuspid Valves: An Update from Dr. Tsuyoshi Kaneko from the 2022 Annual Meeting of the Society of Thoracic Surgeons
Duration: 30 minutes
CEU Value: 1
Expires: April 15, 2023
CSCT CEU STANDARDS SECTION: 2F
Link: TAVR in Bicuspid Valves: Update from STS 2022 | myCME
Description:
Program Description
Dr. Tsuyoshi Kaneko lends an expert perspective on the rapidly growing evidence base on the role of transcatheter aortic valve replacement (TAVR) in patients with bicuspid valve anatomy, including the most recent data presented at the 2022 annual meeting of the Society of Thoracic Surgeons (STS). While outcomes can rival those seen with traditional surgical valve replacement, Dr. Kaneko notes important caveats regarding proper patient selection that underscore the need for assessment by a heart valve team when deciding between the two approaches.
Strategies for Individualizing PAH Treatment to Ensure Optimal Patient Outcomes
Duration: 1 hour
CEU Value: 1
Expires: June 9, 2023
CSCT CEU STANDARDS SECTION: 2F
Link: Individual PAH Treatment to Ensure Optimal Outcomes | myCME
Description:
Program Description
In this activity, leading experts discuss appropriate diagnostic measures that differentiate pulmonary arterial hypertension (PAH) from other disorders. Additionally, these experts will provide strategies on individualizing treatment for patients with PAH based on the latest practice-altering clinical trial data in the field of PAH.
Novel Agents Targeting the Source of HCM Disease
Duration: 30 minutes
CEU Value: 0.5
Expires: May 10, 2023
CSCT CEU STANDARDS SECTION: 2F
Link: Novel Agents Targeting the Source of HCM Disease | myCME
Description:
Program Description
Hypertrophic cardiomyopathy (HCM) is prevalent around the world, with a conservatively estimated 20 million individuals affected. Even in developed countries, current management of HCM is suboptimal. Much has been learned over the past 2 decades about the pathophysiology of HCM and new therapies such as mavacamten, CK-274, IMB-101, and CT-G20 are currently being developed and tested in clinical trials addressing the underlying pathophysiology of HCM. Although these new agents are in late stages of development, clinicians are often not fully up to date on this progress and the potential opportunity to improve care for patients.
Please join Drs. Maron and Rakowski in this final installment of a CMEO Snack series on HCM as they discuss methods to assess study results of emerging HCM disease-specific treatments targeting cardiac myosin in order to optimize outcomes for patients.
HCM Around the Globe: Not an Isolated Issue
Duration: 30 minutes
CEU Value: 0.5
Expires: May 10, 2023
CSCT CEU STANDARDS SECTION: 2F
Link: HCM Around the Globe: Not an Isolated Issue | myCME
Description:
Program Description
Hypertrophic cardiomyopathy (HCM) is an under-recognized, common, and treatable genetic disease occurring worldwide. HCM is a myocardial disorder most often caused by mutations in one of several sarcomere genes that encode components of the contractile apparatus of the heart. It is characterized by ventricular hypertrophy that cannot be explained by another cardiac or systemic disease. Adding to the burden of disease, HCM can present with a variety of symptoms mimicking other conditions and may go undiagnosed for many years and it is estimated that approximately one in 500 individuals in the United States may have clinically unrecognized, undiagnosed HCM, with an overall prevalence estimated at 750,000.
Please join Dr. Maron and Dr. Torres in this first installment of a CMEO Snack series as they discuss strategies for optimal screening of HCM in an effort to increase recognition and diagnosis of this too often misdiagnosed disease.
Racial Disparities in Cardiac Arrhythmia Care: A Call to Action
Duration: 45 minutes
CEU Value: 1
Expires: March 3, 2023
CSCT CEU STANDARDS SECTION: 2F
Link: Racial Disparities in Cardiac Arrhythmia Care | myCME
Description:
Program Description
Statement of Need
Racial disparitiesin potentially life-saving interventional cardiology care exist and persist even with otherwise equal access to care. Untreated or undertreated cardiac arrhythmias, such as atrial fibrillation (AF) can have serious consequences, including heart failure (HF)and stroke. Action steps for clinicians to help mitigate health disparities in cardiac arrythmia care include increased awareness of disparities and improved adherence to guidelines for HF management.
In this CME Outfitters BriefCase, expert faculty will present two to three patient cases that will showcase how clinicians can integrate best practices to mitigate disparities in the management of cardiac rhythm disorders across race, ethnicity, and gender.
Appropriate Use of SGLT2s and GLP-1RAs with Insulin to Reduce CVD Risk in Patients with Diabetes
Duration: 1 hour
CEU Value: 1
Expires: December 27, 2022
CSCT CEU STANDARDS SECTION: 2F
Link: Treatments to Reduce CVD Risk in Patients with Diabetes | myCME
Description:
Program Description
Patients with type 2 diabetes mellitus are prone to hypertension, dyslipidemia, and coronary artery disease leading to a high risk of myocardial infarction, heart failure, and stroke in these patients. Adequate control of diabetes mellitus is essential to mitigate this risk, and underlying co-morbidities such as hypertension and dyslipidemia must be well controlled to minimize cardiovascular risks in patients with type 2 diabetes. However, there is no set algorithm to achieve this target, and a patient-centered approach, evaluating their specific risk factors, is warranted. Choice of medical therapy should be individualized to obtain the best possible outcome for each patient. Initial treatment rests on educating the patient about glycemic control and appropriate lifestyle changes such as tobacco cessation, increasing exercise, and reducing body weight. However, patients with established cardiovascular disease or those at high risk of this disease warrant special consideration to prevent poor outcomes. This activity describes the evaluation and management of cardiovascular risks in patients with type 2 diabetes mellitus and emphasizes using sodium-glucose co-transporter 2 (SGLT2) inhibitors and glucagon-like peptide 1 receptor antagonist (GLP-1RA) drugs in conjunction with insulin to mitigate this risk. It also highlights the role of the interprofessional team in improving care for patients with these conditions.
Cardiac Amyloidosis: Accelerating Diagnosis and Treatment
Duration: 1 hour
CEU Value: 2 (All Components must be completed)
Expires: December 27, 2022
CSCT CEU STANDARDS SECTION: 2F
Link: Cardiac Amyloidosis: Accelerating Diagnosis and Treatment
Description:
Program Description
Podcast
Red Flags/Clinical Clues for Considering Cardiac Amyloidosis
Patient Case Quiz
Diagnosis of LVH
When to Suspect Cardiac Amyloidosis
Slide Lecture
Red Flags and Clinical Clues - When to Suspect Cardiac Amyloidosis
Heart Failure with Preserved Ejection Fraction as an Exercise Deficiency Syndrome: JACC Focus Seminar
Duration: 1 hour
CEU Value: 1 (All Components must be completed)
Expires: December 27, 2022
CSCT CEU STANDARDS SECTION: 2F
Program Description
Across differing spectrums of cardiac function and cardiac pathologies, there are strong associations between measures of cardiorespiratory fitness and burden of symptoms, quality of life, and prognosis. In this part 2 of a 4-part series, we contend that there is a strong association among physical activity, cardiorespiratory fitness, and cardiac function. We argue that a chronic lack of exercise is a major risk factor for heart failure with preserved ejection fraction in some patients. In support of this hypothesis, increasing physical activity is associated with greater cardiac mass, greater stroke volumes, greater cardiac output and peak oxygen consumption, and fewer clinical events. Conversely, physical inactivity results in cardiac atrophy, reduced output, reduced chamber size, and decreased ability to augment cardiac performance with exercise. Moreover, physical inactivity is a strong predictor of heart failure risk and death. In sum, exercise deficiency should be considered part of the broad heart failure with preserved ejection fraction phenotype.
Transvenous Right Greater Splanchnic Nerve Ablation in Heart Failure and Preserved Ejection Fraction: First-in-Human Study
Duration: 1 hour
CEU Value: 1 (All Components must be completed)
Expires: December 27, 2022
CSCT CEU STANDARDS SECTION: 2F
Program Description
Background
Ablation of the right-sided greater splanchnic nerve (GSN) can reduce excessive splanchnic vasoconstriction, potentially improving the handling of volume shifts in patients with heart failure with preserved ejection fraction (HFpEF).
Objectives
The purpose of this study was to assess a novel catheter procedure of right sided GSN ablation to treat HFpEF: splanchnic ablation for volume management.
CEU Opportunities
Cardiocases Web Site
Pacing & Defibrillation
Unique and guided training
New EP cases
Train yourself using our online electrophysiology system.
Take this course and earn 10 CEU'S for the full suite!
New CEU Survey!
A new Continuing Education Unit Survey was released and your participation to shape the future of Cardiology Technologists in the province is in your hands. We encourage you to respond so we can help you succeed!